Feb. 19, 2015
First Friday Seminar to focus on early treatment of Type 2 diabetes
Matthew L. Bird, Pharm.D., medical science liaison for diabetes at AstraZeneca in Oklahoma City, will discuss early treatment of Type 2 diabetes at noon on Friday, March 6.
The seminar, “Rationale for Early Intensive Treatment of Type 2 Diabetes Mellitus with Combination Therapy,” will examine the advantage of early intensive treatment with a combination of pharmaceuticals for patients with Type 2 diabetes.
Bird earned his bachelor’s degree in biology and his Doctor of Pharmacy at Southwestern Oklahoma State University in Weatherford. He was an assistant professor at the University of Oklahoma College of Pharmacy prior to joining AstraZeneca.
The seminar will be in D-107 and is free and open to the public. It is presented by the OSU-CHS Department of Pharmacology and Physiology.